Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen: https://doi.org/10.21256/zhaw-21359
Publikationstyp: Beitrag in wissenschaftlicher Zeitschrift
Art der Begutachtung: Peer review (Publikation)
Titel: Natural ghrelin in advanced cancer patients with cachexia : a case series
Autor/-in: Blum, David
de Wolf-Linder, Susanne
Oberholzer, Rolf
Brändle, Michael
Hundsberger, Thomas
Strasser, Florian
et. al: No
DOI: 10.1002/jcsm.12659
10.21256/zhaw-21359
Erschienen in: Journal of Cachexia, Sarcopenia and Muscle
Band(Heft): 12
Heft: 2
Seite(n): 506
Seiten bis: 516
Erscheinungsdatum: 15-Jan-2021
Verlag / Hrsg. Institution: Wiley
ISSN: 2190-5991
2190-6009
Sprache: Englisch
Schlagwörter: Appetite; Cancer cachexia; Ghrelin; Muscle mass
Fachgebiet (DDC): 616: Innere Medizin und Krankheiten
Zusammenfassung: Background: Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose‐finding trial of subcutaneous natural ghrelin to improve nutritional intake (NI) in advanced cancer patients. Methods: Advanced cancer patients with cachexia management (symptom management, physiotherapy, nutritional, and psychosocial support) started with ghrelin at 32 μg/kg body weight, followed by 50% dose increases. Patients self‐injected ghrelin twice daily for 4 days followed by a wash‐out period. After reaching the primary endpoint, maximal NI (minimal dose for maximal NI), a maintenance period followed during which patients injected 10 doses of ghrelin per week. Safety parameters, NI, and cachexia outcomes (symptoms, narratives, muscle mass, and strength) were measured over 6 weeks. Results: Ten patients with metastatic solid tumours were included, and six (100% male, mean age 61.8 ± 8.5 SD) received ghrelin. Minimal dose for maximal NI was reached in four patients. Three patients reached the end‐of study visit. Ghrelin was well tolerated with variable results on appetite and eating‐related symptoms but a positive effect in the narratives. Mean Functional Assessment of Appetite & Cachexia Therapy score was 6.8 points lower at final measurement compared with baseline, t(5) = 5.98, P < .01. Muscle mass was stable in two patients and increased in one patient, and muscle strength was stable in three patients. Subjective tolerability was high. Patients showed a fluctuating trajectory, and median survival was 88 days (51–412 days). Conclusions: Ghrelin was safe in advanced patients with cancer cachexia without dose‐limiting toxicity and well tolerated. The intervention was very complex, and the number of patients included was small. There was a positive effect on nutritional intake and patient narratives.
URI: https://digitalcollection.zhaw.ch/handle/11475/21359
Volltext Version: Publizierte Version
Lizenz (gemäss Verlagsvertrag): CC BY 4.0: Namensnennung 4.0 International
Departement: Gesundheit
Organisationseinheit: Institut für Pflege (IPF)
Enthalten in den Sammlungen:Publikationen Gesundheit

Dateien zu dieser Ressource:
Datei Beschreibung GrößeFormat 
2021_Blum_etal_Natural-ghrelin-in-advaned-cancer-patients_jcsm.pdf443.42 kBAdobe PDFMiniaturbild
Öffnen/Anzeigen
Zur Langanzeige
Blum, D., de Wolf-Linder, S., Oberholzer, R., Brändle, M., Hundsberger, T., & Strasser, F. (2021). Natural ghrelin in advanced cancer patients with cachexia : a case series. Journal of Cachexia, Sarcopenia and Muscle, 12(2), 506–516. https://doi.org/10.1002/jcsm.12659
Blum, D. et al. (2021) ‘Natural ghrelin in advanced cancer patients with cachexia : a case series’, Journal of Cachexia, Sarcopenia and Muscle, 12(2), pp. 506–516. Available at: https://doi.org/10.1002/jcsm.12659.
D. Blum, S. de Wolf-Linder, R. Oberholzer, M. Brändle, T. Hundsberger, and F. Strasser, “Natural ghrelin in advanced cancer patients with cachexia : a case series,” Journal of Cachexia, Sarcopenia and Muscle, vol. 12, no. 2, pp. 506–516, Jan. 2021, doi: 10.1002/jcsm.12659.
BLUM, David, Susanne DE WOLF-LINDER, Rolf OBERHOLZER, Michael BRÄNDLE, Thomas HUNDSBERGER und Florian STRASSER, 2021. Natural ghrelin in advanced cancer patients with cachexia : a case series. Journal of Cachexia, Sarcopenia and Muscle. 15 Januar 2021. Bd. 12, Nr. 2, S. 506–516. DOI 10.1002/jcsm.12659
Blum, David, Susanne de Wolf-Linder, Rolf Oberholzer, Michael Brändle, Thomas Hundsberger, and Florian Strasser. 2021. “Natural Ghrelin in Advanced Cancer Patients with Cachexia : A Case Series.” Journal of Cachexia, Sarcopenia and Muscle 12 (2): 506–16. https://doi.org/10.1002/jcsm.12659.
Blum, David, et al. “Natural Ghrelin in Advanced Cancer Patients with Cachexia : A Case Series.” Journal of Cachexia, Sarcopenia and Muscle, vol. 12, no. 2, Jan. 2021, pp. 506–16, https://doi.org/10.1002/jcsm.12659.


Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.